Navigation Links
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion)

tere induced an anaphylactoid type reaction consistent with hypersensitivity reactions, including acute increases in blood histamine levels and decreased blood pressure. In contrast, no hypersensitivity reactions, including no elevations in histamine levels and no changes in blood pressure were observed following dosing with ANX-514.

ADVENTRX is continuing to conduct additional preclinical pharmacokinetic testing of ANX-514 to compare this product candidate with the approved version of the product, marketed under the brand name Taxotere. The Company currently plans to seek guidance from the FDA with respect to the appropriateness of a Section 505(b)(2) NDA regulatory path for ANX-514, and pending agreement on clinical protocol design with the FDA, initiate a marketing-enabling clinical trial of ANX-514 in 2007.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a product marketed under the brand name Taxotere. ANX-514 is designed to eliminate the need for multi-day immunosuppressant premedication. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of allergic reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers. In connection with a Section 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable Taxotere patents have expired prior to the manufacture, use or sale of ANX-514.

About Section 505(b)(2)

Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows the Food and Drug Administration (FDA) to approve a follow-on drug on the basis of data in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... (Nasdaq: YDNT ) today announced that it will ... on-demand web cast conference call on Thursday, October 21, 2010 ... the call will be available through InterCall at http://tinyurl.com/Quarter32010 ... available through the Company,s website, www.ydnt.com . ...
... one of the world,s largest and most sophisticated pharmacies ... (D-Nev.), today said innovative companies such as Medco Health ... bright future for a sustainable healthcare system for America ... Nevada by providing employment opportunities for skilled healthcare professionals. ...
Cached Medicine Technology:Young Innovations, Inc. Provides 3rd Quarter Conference Call Details 2Sen. Harry Reid to Medco Employees: Technology and Innovation Integral to Sustainable Healthcare Reform and Nevada's Future 2Sen. Harry Reid to Medco Employees: Technology and Innovation Integral to Sustainable Healthcare Reform and Nevada's Future 3
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce that ... at North Carolina State’s College of Veterinary Medicine has ... for Distinguished Volunteer Service—the organization’s highest award. , ... volunteer experts to direct its work to improve the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... US-based Redux Beverages said it would be marketing. Well, only it was ... drink. ,In September last year it announced the launch ... illegal drug. ,Jamey Kirby, the drink's inventor, said the name ... session at 1 o'clock in the morning. ,"It's an ...
... Cedars-Sinai Medical Center in Los Angeles have reported that they ... who had died and retransplanted it in another recipient. ... has been done with a transplanted heart, said Dr. Lawrence ... program. Even with other organs, repeat transplantation is very rare. ...
... nerve cells signal to one another could rewrite the textbooks ... Weill Cornell Medical College and Yale University. ,Their ... Science, suggests that a key cellular enzyme called dynamin 1 ... previously assumed. ,Dynamin has long been a focus ...
... Children's Research Hospital have discovered inherited variations in certain ... (ALL) susceptible to the toxic side effects caused by ... polymorphisms, occur in specific genes known to influence pharmacodynamics ... drug is needed to have its intended effect). ...
... blood pressure and additional risk factors for heart ... rather than two , if their current treatment ... pressure-lowering medication amlodipine, researchers reported at the American ... Care and Outcomes Research in Cardiovascular Disease and ...
... mother's love is something we all treasure.; Same is the case ... Delhi . ,She has something special planned for her ... wished to be with her mother on Sunday, which is now ... her spirits down. Last time when I was in Delhi, I ...
Cached Medicine News:Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 2Health News:'Cocaine' Turns 'Censored' and Remains 'energy Drink' 3Health News:Transplanted Heart Goes to a Second Recipient in a Rare Surgery 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 2Health News:Study Revises Dynamin's Role in Nerve Cell Function 3Health News:Inherited Genes Linked to Toxicity of Leukemia Therapy 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 2Health News:One Pill may Be Better Than Two for Treating Patients With High Blood Pressure 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: